HomeCancerBreastQuality Outcome Data

Breast Survival Outcomes

PrintE-mail

Survival
RPCI survival data are compared to National Cancer Institute SEER program data, and to quality measures from the National Cancer Data Base of the Commission on Cancer. The survival data for breast cancer show that RPCI patients fare at least as well as, or better than, the national average when compared by cancer stage.

5-Year Relative Survival
Breast Survival Outcomes 5-Year Relative Survival

Surveillance, Epidemiology, and End Results (SEER) Program: (www.seer.cancer.gov): SEER*Stat Database: Incidence - SEER 17 Regs Research Data, Nov 2005 Sub (1973-2003 varying) - Linked To County Attributes - Total U.S., 1969-2003 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.

NCCN Guidelines Compliance 2009
Breast Survival Outcomes NCCN Guidelines Compliance 2009

Comparative Quality Measures
Quality measures reviewed on every patient include specific measures approved by the National Quality Forum, and measures developed from the NCCN Clinical Practice Guidelines. However, as with all quality measures, it is expected, for many reasons (e.g., patient preference, medical contraindications), that concordance with a measure will NEVER be 100%.

Performance Rates Women Under Age 70
Breast Survival Outcomes Performance Rates Women Under Age 70

Comparison of Estimated Performance Rates for Breast Cancer Diagnosed in 2008
The performance rates below have been computed based on data directly reported from RPCI’s Cancer Registry, and are compared to national benchmarks. Once again, the care of RPCI patients who did not receive treatment was carefully reviewed. Most notable is the second table showing chemotherapy in hormone receptor negative cancer. These cases were nonconcordant for two reasons: a few patients decided not to undergo chemotherapy because of personal and medical reasons; and a number received treatment, but just a few days outside the 120 day time window stipulated in the measure.

The estimated performance rates for the groups compare the proportion of women under age 70 who received adjuvant radiation therapy within one year of breast-conserving surgery.

Combination Chemo Women Under Age 70
Breast Survival Outcomes Combination Chemo Women Under Age 70

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer.

Third Generation Aromatase
Breast Survival Outcomes Third Generation Aromatase

 

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast cancer.

Cancer Can't Win

More patients are being diagnosed with cancer every day.

Here at Roswell Park Cancer Institute, we must continue to do what we do best – to understand, prevent and cure cancer. Because if we don’t, cancer wins. And Cancer Can’t Win.

  • With more than 3,000 scientific, academic and medical minds – Cancer Can’t Win.
  • When we are leading an advanced genetic program and creating next generation cancer vaccines to prevent it – Cancer Can’t Win.
  • When we are starting 13 new companies to advance our discoveries and share them with the world – Cancer Can’t Win.

Learn more about why Cancer Can’t Win

close